IFF Announces Executive Leadership Team Aligned With New Operating Model
IFF (NYSE: IFF) announced changes to its executive leadership team, aligned with the Company’s external reporting structure.
After 21 years of dedicated service to IFF, Simon Herriott, president of Health and Biosciences, will step down. Effective March 1, Leticia Gonçalves, ADM’s president of precision fermentation and ADM Ventures, will join IFF as president of Health and Biosciences.
“Since 2019, Simon has driven growth and operational effectiveness through innovation, customer intimacy and supply chain development as president of our Health and Biosciences business unit,” said Erik Fyrwald, IFF CEO. “We’re grateful for Simon’s tremendous contributions to IFF and wish him well for the future. His dedication and leadership will leave a lasting impact on our organization.”
Gonçalves brings to IFF extensive experience with IFF’s end markets in innovation-based companies, having served in various senior global and regional P&L leadership roles at ADM, Bayer and Monsanto in Brazil, Europe and the United States. She was most recently president of precision fermentation and ventures at ADM, where she developed new businesses to serve growing customer needs across various food, health and wellness, agriculture and industrial applications. She also led ADM’s Specialty Ingredients and Foods businesses driving innovation, culture and productivity to maximize value creation across food security, supply chain resilience and sustainability. She is a board member of Emerson Electric.
“We’re excited to welcome Leticia to IFF,” said Fyrwald. “Her extensive experience driving P&L growth in innovation-led businesses and accelerating high-performing teams—coupled with her knowledge of our end markets—will be a great addition to our leadership team. I’m confident Leticia will continue to build on our cutting-edge biotechnology platform of probiotics, cultures and enzymes and drive our next phase of business growth.”
Also new to the executive leadership team, Andy Muller serves as IFF’s president of Food Ingredients. He joined IFF in December 2024 with a wealth of experience in food ingredients. Most recently, he served as president of Functional Ingredients and Solutions at Corbion where he focused on bakery, meat, dairy, confectionery, beverage industries, pet food and biochemicals. He spent 12 years with Danisco, later DuPont’s Nutrition and Health business, where he grew the business by expanding organizational capabilities, rationalizing the product portfolio, and refocusing efforts on core end-market applications. He serves on the board of PureField Ingredients.
“Andy’s deep experience in food ingredients and knowledge of our business will support our focus to deliver growth in our specialty ingredients business and increased value to our customers. We’re excited to have him on board as we continue to grow and innovate.”
Yuvraj Arora, previously President, Nourish, has assumed the role of President, Taste and Chief Commercial Officer. Ana Paula Mendonça, President, Scent, and Angela Strzelecki, President, Pharma Solutions, maintain their current divisional leadership roles.
IFF’s executive leadership team now includes:
- Erik Fyrwald, CEO
- Michael DeVeau, EVP, Chief Financial Officer
- Yuvraj Arora, President, Taste and Chief Commercial Officer
- Ana Paula Mendonça, President, Scent
- Leticia Gonçalves, President, Health & Biosciences
- Andy Muller, President, Food Ingredients
- Angela Strzelecki, President, Pharma Solutions
- Deborah Borg, EVP, Chief People & Culture Officer
- Ralph Finzel, EVP, Global Operations Officer
- Vic Verma, EVP, Chief Information Officer
- Jennifer Johnson, EVP, General Counsel and Corporate Secretary
- Steve Landsman, EVP, Business Development
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.
© 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220609936/en/
Contacts
Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com
Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press Release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 12:00:00 CET | Press Release
Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder of Safe Software. “We’re proud to help organizations integrate data seamlessl
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press Release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande
Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar
FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press Release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a major step forward in the professionalisation and global development of the sport. First introduced in 1981, the Concorde Agreements are designed to promote sporting fairness, technological innovation and operational excellence, and align all key stakeholders around a shared vision for structured governance and continued growth of the sport. Each iteration of the Concorde Agr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom